1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-Buten-1-one | 936563-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-Buten-1-one
• 英文别名: 1-[3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]but-2-en-1-one
• CAS: 936563-88-1
• 化学式: C₂₆H₂₆N₆O₂
• 分子量: 454.5
• InChiKey: KOMVUMRPJMRZLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Honigberg Lee

  公开号：US20080076921A1

  公开（公告）日：2008-03-27

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与Bruton酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。披露了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗药物结合，用于治疗自身免疫疾病或状况、异体免疫疾病或状况、癌症，包括淋巴瘤，以及炎症性疾病或状况。
• Methods and Compositions for Inhibition of Bone Resorption
  申请人：Buggy Joseph J.

  公开号：US20130178483A1

  公开（公告）日：2013-07-11

  Disclosed herein are methods and compounds for inhibiting bone and/or cartilage resorption in an individual. The methods comprise administering to the individual a composition comprising a therapeutically effective amount of a compound that is an irreversible inhibitor of a Bruton's tyrosine kinase (BTK), or a pharmaceutically acceptable salt thereof. Also described are irreversible inhibitors of Btk and methods for the preparation of the compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the inhibition of cancer metastasis, and for inhibition of bone or cartilage resorption in cancer patients.

  本文披露了一种用于抑制个体骨骼和/或软骨吸收的方法和化合物。该方法包括向个体投予含有治疗有效量的某种化合物的组合物，该化合物是布氏酪氨酸激酶（BTK）的不可逆抑制剂或其药用可接受的盐。还描述了BTk的不可逆抑制剂及该类化合物的制备方法。还披露了包括这些化合物的药物组合物。披露了使用BTk抑制剂的方法，单独或与其他治疗剂联合使用，用于抑制癌症转移，以及用于抑制癌症患者的骨骼或软骨吸收。
• BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING
  申请人：PAN Zhengying

  公开号：US20080214501A1

  公开（公告）日：2008-09-04

  Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.

  本文描述了用于布鲁顿酪氨酸激酶（Btk）的探针。这些探针用于表征和开发旨在治疗用途的Btk选择性抑制剂。
• INHIBITORS OF B LYMPHOCYTE KINASE
  申请人：Honigberg Lee

  公开号：US20120165328A1

  公开（公告）日：2012-06-28

  Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

  本文描述了不可逆激酶抑制剂化合物的方法，合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。此外，本文还描述了用于确定蛋白质（包括激酶）适当的不可逆抑制剂的方法、测定和系统。
• Inhibitors of BMX non-receptor tyrosine kinase
  申请人：Honigberg Lee

  公开号：US20120184013A1

  公开（公告）日：2012-07-19

  Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

  本文描述了不可逆激酶抑制剂化合物，合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。此外，本文还描述了确定蛋白质（包括激酶）的适当不可逆抑制剂的方法、测定和系统。